Potential role of immune modulation in the effective long-term control of HIV-1 infection.

Détails

ID Serval
serval:BIB_23775
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Potential role of immune modulation in the effective long-term control of HIV-1 infection.
Périodique
Journal of Biological Regulators and Homeostatic Agents
Auteur(s)
Rizzardi G.P., Lazzarin A., Pantaleo G.
ISSN
0393-974X
Statut éditorial
Publié
Date de publication
2002
Peer-reviewed
Oui
Volume
16
Numéro
1
Pages
83-90
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
Recent advances in HIV-1 pathogenesis, and in defining virological and immunological responses to highly active antiretroviral therapy (HAART), along with the identification of the numerous drawbacks of HAART, have clearly demonstrated that the eradication of the virus is not a feasible therapeutic goal, and that there is an urgent need to develop other approaches to fight HIV-1 infection. Novel therapeutic approaches of immune modulation have recently been evaluated in pilot clinical trials. First, treating primary HIV-1 infection with cyclosporin A (CsA) coupled with HAART to target massive immune activation extends the benefits achieved with HAART during primary HIV-1 infection and might contribute to the establishment of a more favourable immunological set-point affecting the ultimate pattern and rate of disease progression. Second, treating chronic HIV-1 infection in patients with long-term suppression of virus replication induced by HAART, with the addition of mycophenolate mofetil (MMF) reduces the pool of activated CD4+ T lymphocytes able to support productive HIV-1 infection, and might have an indirect impact on the pool of resting, latently infected CD4+ T cells, contributing to its depletion in vivo. The important question is clearly whether these results will have an impact on the clinical management of patients with HIV-1 infection, determining the precise therapeutic function of drugs like CsA and MMF, thus investigating the effects of these drugs on residual viral replication and the decay of the latent reservoir, on long-term immunological benefit, and, ultimately, on clinical benefit.
Mots-clé
Adjuvants, Immunologic/therapeutic use, Animals, Anti-HIV Agents/therapeutic use, Antiretroviral Therapy, Highly Active, CD4-Positive T-Lymphocytes/drug effects, CD4-Positive T-Lymphocytes/virology, Clinical Trials as Topic, Cohort Studies, Cyclosporine/pharmacology, Cyclosporine/therapeutic use, Disease Progression, Drug Therapy, Combination, HIV Infections/drug therapy, HIV Infections/epidemiology, HIV-1/drug effects, HIV-1/immunology, Haplorhini, Humans, Immunosuppressive Agents/pharmacology, Immunosuppressive Agents/therapeutic use, Lymphocyte Activation/drug effects, Mycophenolic Acid/analogs &amp, derivatives, Mycophenolic Acid/pharmacology, Pilot Projects, Virus Replication/drug effects
Pubmed
Web of science
Création de la notice
19/11/2007 13:19
Dernière modification de la notice
20/08/2019 14:01
Données d'usage